Testosterone Replacement Therapy TRT Hormone

by Dr. Randy Smith of Antiaging Atlanta

TRT Testosterone Replacement Therapy improved body composition and insulin sesnsitivity in men with type 2 diabetes.


2016 Oct;18(10):980-9. doi: 10.1111/dom.12701. Epub 2016 Jul 12.

Effect of testosterone on insulin sensitivity, oxidative metabolism and body composition in aging men with type 2 diabetes on metformin monotherapy.



To evaluate the effect of testosterone replacement therapy (TRT) on body composition, insulin sensitivity, oxidative metabolism and glycaemic control in aging men with lowered bioavailable testosterone (BioT) levels and type 2 diabetes mellitus (T2D) controlled on metformin monotherapy.


We conducted a randomized, double-blind, placebo-controlled study in 39 men aged 50-70 years with BioT levels <7.3 nmol/L and T2D treated with metformin monotherapy. Patients were randomized to testosterone gel (TRT, n = 20) or placebo (n = 19) for 24 weeks. Lean body mass (LBM), total and regional fat mass were measured using whole-body dual-energy X-ray absorptiometry scans. Whole-body peripheral insulin sensitivity, endogenous glucose production (EGP) and substrate oxidation were assessed by euglycaemic-hyperinsulinaemic clamp with glucose tracer and combined with indirect calorimetry. Coefficients (β) represent the placebo-controlled mean effect of intervention.


LBM (β = 1.9 kg, p = 0.001) increased after TRT, while total fat mass (β = -1.3 kg, p = 0.009), fat mass trunk (β = -0.7 kg, p = 0.043), fat mass legs (β = -0.7 kg, p = 0.025), fat mass arms (β = -0.3 kg, p = 0.001), and HDL cholesterol (β = -0.11 mmol/L, p = 0.009) decreased after TRT compared with placebo. Insulin-stimulated glucose disposal rates did not change in response to TRT compared with placebo (p = 0.18). Moreover, glycated haemoglobin, and basal and insulin-stimulated rates of EGP, lipid- and glucose-oxidation were unaltered after TRT.


TRT in aging men with lowered BioT levels and T2D controlled on metformin monotherapy improved body composition; however, glycaemic control, peripheral insulin sensitivity, EGP and substrate metabolism were unchanged.

© 2016 John Wiley & Sons Ltd.


clinical trial; insulin sensitivity; male hypogonadism; testosterone therapy; type 2 diabetes mellitus


  Personal Message from Dr. Smith

My primary goal at AntiagingAtlanta is to enhance your quality of life through providing a comprehensive approach to antiaging medicine.

I am committed to providing you with the best Antiaging Medicine program available.

Call me today and schedule your Antiaging Medicine evaluation.


Dr. Randy Smith



Antiaging Atlanta
12600 Deerfield Parkway
Suite 100
Alpharetta, Georgia 30004

Phone: 678-566-3602

Call today today and speak with Dr. Smith to schedule your personal Agntiaging Medicine evaluation.

Getting Started

To unsubscribe to our newsletter email Dr. Smith at:

Dr. Smith